You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

squamous non-small cell lung cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Squamous Non Small Cell Lung Cancer Trial (AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel)

Not yet recruiting
  • Advanced Squamous Non Small Cell Lung Cancer
  • AK112, Carboplatin, Paxlitaxel
  • Tislelizumab, Carboplatin, Paxlitaxel
  • (no location specified)
Apr 21, 2023

Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)

Not yet recruiting
  • Advanced Squamous Non-Small-Cell Lung Cancer
  • (no location specified)
Jun 11, 2023

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Ivonescimab Injection
  • Pembrolizumab Injection
  • (no location specified)
Jun 9, 2023

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 16, 2023

Non-squamous NSCLC, Epithelial Ovarian Cancer Trial (AMG 794)

Not yet recruiting
  • Non-squamous Non-small Cell Lung Cancer
  • Epithelial Ovarian Cancer
  • AMG 794
  • Orange, California
    University of California at Irvine
Jan 25, 2023

Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

Not yet recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 5, 2023

Non Squamous Non Small Cell Lung Cancer Trial in Korea, Republic of (Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
  • Anam, Korea, Republic of
  • +7 more
May 1, 2023

Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

Not yet recruiting
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 20, 2023

Advanced Non-squamous Non-Small-Cell Lung Cancer Trial in Jinan (Sintilimab)

Recruiting
  • Advanced Non-squamous Non-Small-Cell Lung Cancer
  • Jinan, Shandong, China
    The First Affiliated Hospital of Shandong First Medical Universi
Dec 4, 2022

Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)

Active, not recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Brain Metastases
  • Guangzhou, Guangzhou, China
    Li-Kun Chen
Nov 13, 2022

NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
  • Wuhan, Hubei, China
    Union hospital
Feb 20, 2023

Non-squamous NSCLC Trial in Guangzhou (FSRT combined with Bevacizumab)

Active, not recruiting
  • Non-squamous Non-small Cell Lung Cancer
  • FSRT combined with Bevacizumab
  • Guangzhou, China
    Sun Yat-sen University
Nov 25, 2022

NSCLC Trial in Pittsburgh (M1774, Cemiplimab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Cancer Center
May 22, 2023

NSCLC Metastatic Trial (bevacizumab plus nab-paclitaxel and platinum)

Not yet recruiting
  • Non-small Cell Lung Cancer Metastatic
  • bevacizumab plus nab-paclitaxel and platinum
  • (no location specified)
Jun 2, 2022

Lung Cancer, Non Small Cell Lung Cancer, Adenocarcinoma of Lung Trial run by the National Cancer Institute (NCI) (LMB-100,

Active, not recruiting
  • Lung Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Oct 4, 2022

NSCLC Trial in Guangzhou (Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Guangzhou, Guang Dong, China
    Sun Yat-sen University Cancer Center
Nov 3, 2022

NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Brain Neoplasms
  • (no location specified)
Dec 9, 2022

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Metastatic Squamous Non-Small Cell Lung Carcinoma Trial in Chicago (Cabozantinib 40 MG, Pembrolizumab 200mg)

Recruiting
  • Metastatic Squamous Non-Small Cell Lung Carcinoma
  • Cabozantinib 40 MG
  • Pembrolizumab 200mg
  • Chicago, Illinois
    University of Illinois at Chicago
Jan 20, 2023

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

Advanced NSCLC Trial in Jilin (pemetrexed, Cetuximab, cis-platinum)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • Jilin, Changchun, China
    Jilin Province Cancer Hospital
Aug 15, 2022

Efficacy Trial in Suzhou (TAB008, Bevacizumab)

Completed
  • Efficacy
  • Suzhou, Jiangsu, China
    TOT
Jun 16, 2022